Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RasGRP4-targeted antisense oligonucleotide
- Development stage
- Preclinical
- Lead developer
- Nissan Chemical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
RasGRP4-targeted antisense oligonucleotide is an antisense oligonucleotide designed to inhibit the expression of Ras guanyl-releasing protein 4 (RasGRP4). RasGRP4 is a guanine nucleotide exchange factor primarily expressed in myeloid cells, including monocytes, macrophages, neutrophils, and mast cells. By downregulating RasGRP4, this therapeutic agent aims to suppress the recruitment and activation of inflammatory monocytes and macrophages, thereby reducing tissue inflammation and muscle injury. It is being developed for the treatment of idiopathic inflammatory myopathies, such as polymyositis and dermatomyositis, as well as rheumatoid arthritis.
- Other names
- RasGRP4 antisense oligonucleotideRasGRP-4 antisense oligonucleotideRasGRP 4 antisense oligonucleotideRasGRP4-targeted ASORasGRP-4-targeted ASORasGRP 4-targeted ASOantisense oligonucleotide of RasGRP4
02
Targets
RASGRP4
Beyond the preview
Go deeper on RasGRP4-targeted antisense oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RasGRP4-targeted antisense oligonucleotide.